CTT Pharma CEO Ryan Khouri detailed the company's roadmap to bring its patented micelle thin-film technology to market in a shareholder communication. The company is preparing to file an S-1 registration statement to access funding through an equity line and transition to an SEC reporting company, a strategic step anticipated to enhance transparency and draw broader investor interest.
The capital secured from this initiative will be allocated toward manufacturing CTT Pharma's oral dissolvable strip products. These include micelle-encapsulated vitamins, bioactive supplements, and nicotine strips, with production objectives set for 2026. Khouri underscored a commitment to prudent management of share count and dilution throughout the funding phase.
To support its commercialization timeline, CTT Pharma is bolstering its team with regulatory specialists to navigate approval pathways for North American sales. The company also intends to hire additional personnel with experience in commercial product launches. Concurrently, CTT Pharma is in the process of selecting a manufacturing facility in the first quarter, followed by the acquisition of necessary production equipment.
A research partnership with Johns Hopkins University continues under a National Institutes of Health grant, investigating the technology as a potential smoking cessation alternative. However, funding for clinical trials remains pending. The company clarified that its core manufacturing and commercialization schedule is not contingent on the NIH's decision regarding this grant.
The company recently reached a significant scientific milestone with the acceptance of a peer-reviewed manuscript for publication on December 15, 2025. Co-authored by scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, the paper offers a comprehensive review of micelle and oral dissolvable strip technology research. This publication is expected to elevate the visibility and comprehension of the scientific foundations underpinning CTT's platform among shareholders, potential collaborators, and the broader scientific community.
Khouri also highlighted ongoing work to fortify the company's patent portfolio and announced plans for a first-quarter conference call to discuss progress and forthcoming initiatives. With capital access on the horizon, CTT Pharma is expanding its team, advancing manufacturing preparations, and defining regulatory strategies to commercialize its innovative drug delivery technology.
